BCV controls both phases of the respiratory cycle. During the inspiratory phase, BCV uses the power of negative pressure to inflate the lungs through a cuirass shell. During the expiratory phase, positive pressure is applied via the cuirass shell, which causes the diaphragm to move back up, facilitating a breath out. BCV is proven to be more physiological than alternative forms of ventilation and is a real alternative for those with failing physiology.
BCV ventilates with Continuous Negative, Control, Synchronized, and Secretion Clearance.
BCV can be used in place of PPV, eliminating mask compliance problems and avoiding intubation.
BCV can be used as a weaning tool from PPV and provides an active expiratory phase.
BCV facilitates true HFCWO, replacing the need for vest and cough assist devices.
The patented technology used in the Hayek RTX provides a very safe means of lung recruitment, offers a means of greatly increasing minute ventilation, and can function as a secretion clearance device with assisted cough. These capabilities enable the RTX to benefit many patients with cardio-pulmonary compromise and respiratory distress. It produces effective ventilation in both normal and injured lungs, in clinical conditions marked by increases in pulmonary shunt and/or increased dead space ventilation.